<DOC>
	<DOCNO>NCT02312882</DOCNO>
	<brief_summary>The purpose study investigate ability tofacitinib citrate , Janus kinase inhibitor , generate hair regrowth patient moderate severe alopecia areata variant .</brief_summary>
	<brief_title>Tofacitinib Treatment Alopecia Areata Its Variants</brief_title>
	<detailed_description>This study open-label pilot study . Participants treat oral tofacitinib 3 month . Participants evaluate 6 month completion therapy evaluate durability response , late response and/or late adverse effect .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Age &gt; = 18 year old Diagnosis alopecia areata &gt; 50 % scalp involvement , alopecia totalis , alopecia universalis Hair loss present least 6 month No treatment alopecia areata past 2 month No evidence hair regrowth Females childbearing potential must use birth control take medication must negative pregnancy test document prior start medication Fluent speak write English Age &lt; 18 year old Patients receive treatment know affect alopecia areata within 2 month enrol study Patients history malignancy ( except history successfully treat basal cell squamous cell carcinoma skin ) Patients known HIV hepatitis B C positive Patients positive tuberculin skin test positive QuantiFERON TB test Patients leukopenia anemia Patients renal hepatic impairment Patients peptic ulcer disease Patients take immunosuppressive medication , include limited prednisone , methotrexate , mycophenolate mofetil , azathioprine , tacrolimus , cyclosporine , TNHalpha inhibitor Women childbearing potential unable unwilling use birth control take medication Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>